A research team composed of members from the National Institutes of Health, Johns Hopkins University, and Florida State University have found two compounds that may protect fetal brains from the Zika virus while preventing the virus from replicating itself inside of its host. The drugs were isolated after screening over 6,000 compounds that are either already FDA-approved, or in some advanced phase of clinical trials. Identifying a therapy that is already approved or nearing approval for other disease states could reduce the amount of time it would take to bring a viable Zika treatment to the public.